While we did not look at MAPK in our analysis, we observed that there was an increase in proliferative markers EGFR and PCNA by PCR and EGF in serum in patients who received sorafenib/RT, which may enhance the proliferation of tumor cells [45]. The gene discussed is PCNA; the disease is neoplasm.